European Economic Area

LunaJets Sees a Hard Landing After the Golden Age

Retrieved on: 
Monday, May 29, 2023

GENEVA, May 29, 2023 /PRNewswire/ --

Key Points: 
  • "Our industry is highly cyclical and exposed to macro swings, we are not surprised by this slowdown in Europe.
  • We had largely anticipated this situation ( LunaJets' Ebace 2022 press release ) but nonetheless remain very concerned by this new market."
  • This international expansion is a testimony of LunaJets' core vision to create the most efficient platform to book a charter anywhere in the world.
  • Supported by its unique expertise LunaJets aims to guarantee access to the best operators, fleet and most recent aircraft using SAF fuel and offsetting their carbon footprint.

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

Retrieved on: 
Wednesday, May 24, 2023

Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.

Key Points: 
  • Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.
  • "We are very excited to extend our existing partnership with Advanz Pharma into additional therapeutic areas.
  • “This partnership positions Advanz Pharma as a key future player in European biosimilars.
  • In February 2023 Alvotech and Advanz Pharma announced that the companies had entered into an exclusive agreement for the commercialization of AVT23, a proposed biosimilar to Xolair® (omalizumab).

RYVYL Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 22, 2023

SAN DIEGO, CA, May 22, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company"), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transaction, has provided its financial results for the first quarter 2023.

Key Points: 
  • SAN DIEGO, CA, May 22, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company"), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transaction, has provided its financial results for the first quarter 2023.
  • FX and international payments business, including Transact Europe, reported over $344 million in business volume during the quarter.
  • We are pleased to report a record first quarter 2023 of $11.3 million, outstanding growth from the prior year of 169%.
  • Management will host a conference at 4:30 p.m. Eastern Time on Monday, May 22, 2023 to discuss first quarter 2023 financial results, provide a corporate update and conclude with a Q&A session.

Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia

Retrieved on: 
Thursday, May 25, 2023

The exclusive license agreement grants Medice the rights to market and sell Vafseo in the European Economic Area in addition to the United Kingdom, Switzerland and Australia.

Key Points: 
  • The exclusive license agreement grants Medice the rights to market and sell Vafseo in the European Economic Area in addition to the United Kingdom, Switzerland and Australia.
  • Anemia associated with CKD, common in patients on dialysis, is a debilitating condition which may be associated with many adverse clinical outcomes.
  • Throughout Europe, we estimate that more than 325,000 dialysis patients are currently treated for anemia associated with CKD.
  • Vafseo is currently approved in Europe and the United Kingdom for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis.

Oerlikon Successfully Placed CHF 340 million Dual-Tranche Senior Unsecured Bonds

Retrieved on: 
Wednesday, May 17, 2023

Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Key Points: 
  • Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
  • This announcement constitutes neither an offer to sell nor a solicitation to buy the bonds described herein (the "Bonds") of OC Oerlikon Corporation AG, Pfäffikon SZ (together with its subsidiaries, "Oerlikon").
  • Relevant information on the Bonds is only available in the final prospectus, which is currently expected to be published on May 25, 2021.
  • Any such projections or statements reflect the current views of Oerlikon about further events and financial performance.

Ikano Bank Digitalizes with NETSOL’s NFS Ascent & Digital Platforms

Retrieved on: 
Tuesday, May 16, 2023

NETSOL’s NFS Ascent and suite of digital solutions are being implemented on the Cloud to support Ikano Bank’s lending to businesses.

Key Points: 
  • NETSOL’s NFS Ascent and suite of digital solutions are being implemented on the Cloud to support Ikano Bank’s lending to businesses.
  • “The partnership with Ikano Bank is a significant project for NETSOL Europe representing the largest multi-country roll-out of our premier platform NFS Ascent.
  • “I would like to thank the entire team at Ikano Bank and those at NETSOL involved in this project.
  • Alongside Ascent, we also deployed NETSOL’s digital touchpoints to further enhance our digital transformation journey and optimize productivity and decision-making.”

Hidden Road Receives Investment Firm License in the Netherlands, Expanding Offering to EU Counterparties

Retrieved on: 
Tuesday, May 16, 2023

This license enables Hidden Road to offer spot and derivative products to institutional counterparties within the European Economic Area.

Key Points: 
  • This license enables Hidden Road to offer spot and derivative products to institutional counterparties within the European Economic Area.
  • This license adds to Hidden Road's growing footprint of licenses, registrations and certifications for the firm's entities around the world.
  • The AFM's approval complements the firm's UK entity, Hidden Road Partners CIV UK Limited, which is an FCA-registered MiFID and AMLD5 investment firm.
  • Together, these registrations enable Hidden Road to offer spot and derivatives products across both traditional and digital assets throughout the EU and UK.

Owens-Brockway Glass Container Inc. and OI European Group B.V. Announce Upsizing and Pricing of Private Green Bond Offerings

Retrieved on: 
Friday, May 12, 2023

OBGC’s obligations under the Dollar Notes will be guaranteed on a joint and several basis by Owens-Illinois Group, Inc. (“OI Group”) and certain U.S. domestic subsidiaries of OI Group that are guarantors under OI Group’s credit agreement.

Key Points: 
  • OBGC’s obligations under the Dollar Notes will be guaranteed on a joint and several basis by Owens-Illinois Group, Inc. (“OI Group”) and certain U.S. domestic subsidiaries of OI Group that are guarantors under OI Group’s credit agreement.
  • The OBGC Offering is expected to close on May 25, 2023, subject to the satisfaction of customary closing conditions.
  • OBGC intends to use the incremental net proceeds from the increase in offering size to fund the repayment or repurchase of near term debt maturities.
  • OIEG’s obligations under the Euro Notes will be guaranteed on a joint and several basis by OI Group, OBGC and certain U.S. domestic subsidiaries of OI Group that are guarantors under OI Group’s credit agreement.

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Retrieved on: 
Friday, May 12, 2023

Post hoc analyses of these data released today assessed whether baseline hormone levels and glucocorticoid (GC) doses correlated with treatment response.

Key Points: 
  • Post hoc analyses of these data released today assessed whether baseline hormone levels and glucocorticoid (GC) doses correlated with treatment response.
  • See the abstract (Poster #274; Response to Crinecerfont Treatment in Adults with Classic Congenital Adrenal Hyperplasia is Correlated with Elevated Baseline Hormone Levels, but Not Glucocorticoid Dose) for more information here .
  • "Androgen excess is a hallmark feature of classic congenital adrenal hyperplasia.
  • These data will be part of an oral presentation (Oral Presentation, May 15, 2:20–2:30pm: Switching Patients with Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control).

Article - Reinforcing European defence: buying weapons together

Retrieved on: 
Thursday, May 11, 2023

Russia’s war against Ukraine underlined the need for the EU to strengthen its defence strategy and speed up weapons production.

Key Points: 
  • Russia’s war against Ukraine underlined the need for the EU to strengthen its defence strategy and speed up weapons production.
  • On 9 May 2023, MEPs agreed to fast track legislation to boost EU production of ammunition and missiles, the so-called Act in Support of Ammunition Production(ASAP).
  • Participation of non-EU countries
    Apart from EU countries, the instrument will also be available to countries that are part of the European Economic Area - Iceland, Liechtenstein and Norway.
  • Read more about how the European Parliament is supporting Ukraine
    How the EU and the Parliament supported Ukraine in 2022
    How the EU and Parliament are supporting Ukraine in 2023